Mach 1 Financial Group LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mach 1 Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 4,393 shares of the biopharmaceutical company’s stock, valued at approximately $841,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. lifted its position in Alnylam Pharmaceuticals by 1.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after acquiring an additional 51 shares during the last quarter. EP Wealth Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 71 shares during the last quarter. Oppenheimer & Co. Inc. raised its position in shares of Alnylam Pharmaceuticals by 2.1% during the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock valued at $800,000 after buying an additional 93 shares during the last quarter. Lindbrook Capital LLC raised its position in shares of Alnylam Pharmaceuticals by 37.2% during the fourth quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 100 shares during the last quarter. Finally, Xponance Inc. raised its position in shares of Alnylam Pharmaceuticals by 0.7% during the third quarter. Xponance Inc. now owns 14,984 shares of the biopharmaceutical company’s stock valued at $2,654,000 after buying an additional 109 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ALNY. Wolfe Research began coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday. Cantor Fitzgerald reissued a “neutral” rating and issued a $165.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Needham & Company LLC reissued a “buy” rating and issued a $200.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $215.88.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded down $3.41 during trading hours on Tuesday, hitting $143.95. 477,037 shares of the stock were exchanged, compared to its average volume of 768,820. The stock has a market capitalization of $18.13 billion, a P/E ratio of -41.39 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $218.88. The business’s 50-day moving average is $150.22 and its two-hundred day moving average is $165.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. During the same quarter in the previous year, the company posted ($1.68) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.